Results 241 to 250 of about 1,152,813 (297)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

Right Temporal Lobe Tuberculoma Presenting as Seizures in a Patient With Pulmonary Tuberculosis. [PDF]

open access: yesAm J Case Rep
Rajanna S   +8 more
europepmc   +1 more source

Interpreting inter- and intra-annual environmental signals in tree-ring δ18O using isotope-enabled modeling. [PDF]

open access: yesTree Physiol
Leppä K   +14 more
europepmc   +1 more source

Metal-Free Synthesis of 1,3-Divinylimidazolidin-2-One. [PDF]

open access: yesChemistryOpen
Lorenzen S   +6 more
europepmc   +1 more source

Multipurpose vaginal rings: preferences from a national discrete choice experiment survey among US women. [PDF]

open access: yesFront Reprod Health
Gottert A   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy